The Cuban biopharmaceutical industry will present the stipulated dossier to the World Health Organization (WHO) in early March with all the information necessary for the prequalification of its anti-Covid-19 vaccines, Eduardo Martínez, director of BioCubaFarma, reported here.
More than four million doses of the Covid-19 Abdala (CIGB-66) vaccine, the first such immunizer conceived and produced in Latin America, have been so far administrated to children and adolescents in Cuba and Nicaragua.
A new solidarity shipment from Russia arrived in Havana with medical supplies for the Cuban health system, amounting to two million dollars.
The first clinical studies of the application of Cuba’s first nasal vaccine candidate, named Mambisa, to patients convalescing from Covid-19 and as a booster are ongoing.
The magazine Chemical Biology of the UK Royal Society of Chemistry reviewed an article about the Cuban vaccine candidate Soberana01 and the advantages of this product against the SARS-CoV-2 coronavirus, media reported on Thursday.